Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA 20114, USA
Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA.
BMJ. 2018 Jun 27;361:k2400. doi: 10.1136/bmj.k2400.
To evaluate the relation between penicillin allergy and development of meticillin resistant (MRSA) and .
Population based matched cohort study.
United Kingdom general practice (1995-2015).
301 399 adults without previous MRSA or enrolled in the Health Improvement Network database: 64 141 had a penicillin allergy and 237 258 comparators matched on age, sex, and study entry time.
The primary outcome was risk of incident MRSA and . Secondary outcomes were use of β lactam antibiotics and β lactam alternative antibiotics.
Among 64 141 adults with penicillin allergy and 237 258 matched comparators, 1365 developed MRSA (442 participants with penicillin allergy and 923 comparators) and 1688 developed (442 participants with penicillin allergy and 1246 comparators) during a mean 6.0 years of follow-up. Among patients with penicillin allergy the adjusted hazard ratio for MRSA was 1.69 (95% confidence interval 1.51 to 1.90) and for was 1.26 (1.12 to 1.40). The adjusted incidence rate ratios for antibiotic use among patients with penicillin allergy were 4.15 (95% confidence interval 4.12 to 4.17) for macrolides, 3.89 (3.66 to 4.12) for clindamycin, and 2.10 (2.08 to 2.13) for fluoroquinolones. Increased use of β lactam alternative antibiotics accounted for 55% of the increased risk of MRSA and 35% of the increased risk of .
Documented penicillin allergy was associated with an increased risk of MRSA and that was mediated by the increased use of β lactam alternative antibiotics. Systematically addressing penicillin allergies may be an important public health strategy to reduce the incidence of MRSA and among patients with a penicillin allergy label.
评估青霉素过敏与耐甲氧西林金黄色葡萄球菌(MRSA)和 发展之间的关系。
基于人群的匹配队列研究。
英国普通实践(1995-2015 年)。
301399 名无既往 MRSA 或 病史且登记在健康改善网络数据库中的成年人:64141 名有青霉素过敏史,237258 名按年龄、性别和研究入组时间匹配的对照者。
主要结局为 MRSA 和 的发病风险。次要结局为β内酰胺类抗生素和β内酰胺类替代抗生素的使用情况。
在 64141 名有青霉素过敏史的成年人和 237258 名匹配的对照者中,1365 名发生了 MRSA(442 名青霉素过敏史患者和 923 名对照者),1688 名发生了 (442 名青霉素过敏史患者和 1246 名对照者),中位随访时间为 6.0 年。在青霉素过敏史患者中,MRSA 的调整后危险比为 1.69(95%置信区间 1.51 至 1.90), 为 1.26(1.12 至 1.40)。青霉素过敏史患者的抗生素使用调整后发病率比值为大环内酯类药物 4.15(95%置信区间 4.12 至 4.17)、克林霉素 3.89(3.66 至 4.12)和氟喹诺酮类药物 2.10(2.08 至 2.13)。β内酰胺类替代抗生素的使用增加占 MRSA 风险增加的 55%,占 风险增加的 35%。
有记录的青霉素过敏与 MRSA 和 的风险增加相关,这种相关性是由β内酰胺类替代抗生素使用增加所介导的。系统地处理青霉素过敏可能是减少有青霉素过敏标签的患者中 MRSA 和 的发病率的一项重要公共卫生策略。